Overview

A Pharmacokinetic Study of Sugammadex in Dialysis Patients

Status:
Withdrawn
Trial end date:
2021-09-10
Target enrollment:
Participant gender:
Summary
The primary objective of this prospective study is to assess the trend of sugammadex (and its complex with rocuronium) concentration in surgical patients with routine outpatient hemodialysis. Patients with end stage renal disease who are to receive general anesthesia and muscle paralysis will have their paralysis by rocuronium reversed with sugammadex. Patients will then have blood drawn during their next three routine hemodialysis sessions to assess for the plasma concentration of sugammadex or the sugammadex-rocuronium complex over time.
Phase:
Phase 1
Details
Lead Sponsor:
Tetsuro Sakai